Frank D. Lee - 12 Jun 2024 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Reporting relationship: Director
Issuer ticker: BOLT
Reported as of: 12 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2024, 18:54:52 UTC
Prior SEC filing: 21 May 2024
Next SEC filing: 13 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ William P. Quinn, Attorney-in-Fact

Key filing fact

Frank D. Lee filed Form 4 for Bolt Biotherapeutics, Inc. (BOLT) on 14 Jun 2024.

Key facts

This page summarizes Frank D. Lee's Form 4 filing for Bolt Biotherapeutics, Inc. (BOLT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2024, 18:54.

Change

Previous filing in this sequence was filed on 21 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BOLT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +22,000
Change %
Price: $0.000000
Shares after: 22,000
Date: 12 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $0.7682
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.